Global Trends Overview: The Rapid Evolution of the Infectious Disease In Vitro Diagnostics Market

The infectious disease in vitro diagnostics sector is set for significant expansion over the coming years. Driven by advancements in technology and rising healthcare needs, this market is evolving rapidly to meet the growing demand for quicker and more accurate diagnostic solutions. Let's explore the market size, key players, influential trends, and segment-wise outlook shaping this important healthcare field.

Projected Market Growth and Size of the Infectious Disease In Vitro Diagnostics Market
The infectious disease in vitro diagnostics market is anticipated to experience robust growth, reaching a valuation of $19.83 billion by 2029. This reflects a compound annual growth rate (CAGR) of 7.0% during the forecast period. The expansion is fueled by increasing demand for point-of-care testing, a rise in infectious disease cases worldwide, growing adoption of personalized medicine, and expanded healthcare infrastructure particularly in emerging economies. Emerging technologies such as next-generation sequencing, microfluidics-based platforms, lab-on-a-chip devices, multiplex polymerase chain reaction (PCR) assays, and digital immunoassays are expected to drive innovation and market momentum.

Download a free sample of the infectious disease in vitro diagnostics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30303&type=smp

Leading Companies Shaping the Infectious Disease In Vitro Diagnostics Market
The market features a range of prominent players actively contributing to its growth and innovation. Key companies include F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare AG, BioMérieux SA, Qiagen N.V., Becton, dic*kinson and Company, Hologic, Inc., Labcorp Holdings Inc., DiaSorin S.p.A., Meridian Bioscience, Quidel Corporation, Quest Diagnostics, Revvity Inc. (formerly PerkinElmer, Inc.), OraSure Technologies, Inc., Transasia Bio-Medicals Ltd., Randox Laboratories, Luminex Corporation, Wako Pure Chemical Industries, Bio-Rad Laboratories Inc., Trivitron Healthcare, and InBios International Inc.

Notable Acquisition Bolstering Innovation and Market Presence
In January 2025, Fremman Capital, a UK-based private equity firm with a focus on healthcare and life sciences, acquired a majority stake in Italy-based DIESSE Diagnostica Senese for an undisclosed sum. This acquisition aims to accelerate DIESSE's global growth and strengthen its leadership in specialty in vitro diagnostics. Fremman Capital plans to support innovation efforts, expand the company's autoimmune and infectious disease diagnostic product lines, and increase production capacity at its advanced biotech campus. DIESSE is known for its innovative testing solutions for autoimmunity, infectious diseases, and hematology, serving clinical laboratories worldwide.

View the full infectious disease in vitro diagnostics market report:
https://www.thebusinessresearchcompany.com/report/global-infectious-disease-in-vitro-diagnostics-market-report

Innovative Trends Enhancing Infectious Disease In Vitro Diagnostics
Leading industry players are focusing on developing cutting-edge products that enable rapid detection of multiple pathogens, particularly for gastrointestinal infectious diseases. These advancements improve diagnostic speed and accuracy, ultimately enhancing patient outcomes and expanding point-of-care testing options.
For example, in June 2024, US-based MP Biomedicals introduced a series of immunochromatographic rapid diagnostic kits capable of detecting key gastrointestinal pathogens such as Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. These kits offer quick qualitative results at the point of care, utilize diverse sample types including stool, blood, plasma, serum, water, and food, and are suitable for both clinical and research applications. Employing advanced immunochromatographic technology, these tests facilitate early diagnosis, treatment monitoring, and confirmation of pathogen clearance, marking a significant breakthrough in gastrointestinal disease diagnostics by combining speed, precision, and broad pathogen coverage.

Market Segmentation Overview of the Infectious Disease In Vitro Diagnostics Market
This market is categorized across multiple dimensions to offer a detailed perspective:
1) By Product Type: Instruments, Reagents, Software and Services
2) By Technology: Molecular Diagnostics, Immunoassay, Microbiology, Hematology, Urinalysis, Other Technologies
3) By Application: Methicillin-Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile, Respiratory Virus, Tuberculosis (TB) and Drug-Resistant Tuberculosis (TB), Gonorrhea, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Hepatitis C, Hepatitis B, Other Applications
4) By End-Use: Hospitals and Clinics, Diagnostic Laboratories, Academic Research Institutes, Other End-Users

Further detailed subsegments include:
- Instruments like Polymerase Chain Reaction Machines, Immunoassay Analyzers, Microbiology Analyzers, Hematology Analyzers, Urinalysis Analyzers, Next Generation Sequencers, and Flow Cytometers
- Reagents including Molecular, Immunoassay, Microbiology, Hematology, Urinalysis Reagents, Enzymes and Buffers, Controls and Calibrators
- Software and Services comprising Data Management Software, Laboratory Information Systems, Cloud-Based Solutions, Maintenance and Support, Consulting and Training Services, and Remote Monitoring Services

This extensive segmentation provides a comprehensive understanding of the components driving growth and innovation within the infectious disease in vitro diagnostics market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.